- Home
- PHAR vs CCRN Comparison
PHAR vs CCRN Comparison
Compare PHAR & CCRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHAR | CCRN |
|---|---|---|
| Founded | 1988 | 1986 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 447.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PHAR | CCRN |
|---|---|---|
| Price | $16.56 | $7.99 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $30.00 | $13.81 |
| AVG Volume (30 Days) | 23.9K | ★ 1.4M |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | $362,274,000.00 | ★ $1,127,472,000.00 |
| Revenue This Year | $24.80 | N/A |
| Revenue Next Year | $6.84 | N/A |
| P/E Ratio | $2,952.77 | ★ N/A |
| Revenue Growth | ★ 26.78 | N/A |
| 52 Week Low | $7.50 | $7.43 |
| 52 Week High | $18.12 | $18.30 |
Technical Indicators
Market Signals| Indicator | PHAR | CCRN |
|---|---|---|
| Relative Strength Index (RSI) | 49.13 | 31.52 |
| Support Level | $16.23 | $7.71 |
| Resistance Level | $17.00 | $8.75 |
| Average True Range (ATR) | 0.77 | 0.41 |
| MACD | -0.16 | 0.01 |
| Stochastic Oscillator | 25.85 | 20.00 |
Price Performance
Historical ComparisonAbout PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About CCRN Cross Country Healthcare Inc. $0.0001 Par Value
Cross Country Healthcare Inc is a provider of total talent management services, including strategic workforce solutions, contingent staffing, permanent placement and consultative services for healthcare customers. The company operates in two business segments: the nurse and allied staffing segment, which generates a vast majority of revenue, offers temporary and permanent placements of travel and local nurses and allied professionals, and other outsourcing services.: the Physician Staffing segment provides licensed practitioners across a broad array of specialties, as well as certified registered nurse anesthetists (CRNAs), nurse practitioners (NPs), and physician assistants (PAs) on temporary assignments. The company earns majority of its revenue from the United States.